The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
Open accessAbstract
Background: Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. Objective: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (Hi SCR) and its utility as an outcome measure. Methods: Patients with baseline total abscess and inflammatory nodule count (AN count) of at least three and draining fistula count of 20 or fewer comprised the post hoc subpopulation analysed. Hi SCR (at least a 50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline) and HS‐PGA Response [Hidradenitis Suppurativa‐Physician's Global Assessment score of clear, minimal, or mild, with at least a 2‐grade improvement from baseline] were used to evaluate patient response after adalimumab treatment weekly, every other week, or placebo (1 : 1 : 1). Results: The subpopulation included 132 (85.7%) patients; 70.5% women and 73.5% white. At week 16, Hi SCR was achieved by 54.5% receiving weekly adalimumab, 33.3% every other week, and 25.6% placebo and HS‐PGA Response was achieved by 20.5% receiving weekly adalimumab, 6.7% every other week and 2.3% placebo. Conclusion: Hi SCR was more responsive to change than HS‐PGA Response in this subpopulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comorbidities of hidradenitis suppurativa (acne inversa)
Fimmel, S., & Zouboulis, C. C. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.1.12490 · Cited by 245
Cited by
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 807
Self-citationSabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Self-citationHidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
Self-citationGoldburg, S. R., Strober, B. E., & Payette, M. J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.090 · Cited by 486
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.067 · Cited by 400
Self-citation
Metadata
- Authors
- Kimball, A. B., Sobell, J. M., Zouboulis, C. C., Gu, Y., Williams, D. A., Sundaram, M., Teixeira, H. D., & Jemec, G. B. E.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2015-07-22
- Volume
- 30
- Issue
- 6
- Pages
- 989-994
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W2163545413
- Cited by
- 202
- References
- 1
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.